H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days

Rhea-AI Summary

H-CYTE, Inc. (OTCQB: HCYT) has announced its acquisition of Jantibody, an immunotherapeutic agent under investigation for treating ovarian cancer, expected to close within 30 days. This milestone is part of H-CYTE's strategy to diversify its asset portfolio. The company plans to submit a Pre-IND submission for Jantibody in the latter half of 2022, aiming for Orphan Drug Designation that grants 7-year market exclusivity. Jantibody has shown strong efficacy in preclinical studies for ovarian cancer and potentially other cancers.

Positive

• Acquisition of Jantibody enhances H-CYTE's asset portfolio focused on ovarian cancer.
• Potential market exclusivity for Jantibody with Orphan Drug Designation.
• Robust efficacy of Jantibody in preclinical models against difficult-to-treat cancers.

Negative

• None.

Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset Portfolio

TAMPA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company expects to close its acquisition of Jantibody within the next 30 days for an undisclosed amount.

Highlights:

• Milestone achieved as H-CYTE advances plans to build a diverse asset portfolio
• Focus indication for ovarian cancer with the potential to be used for other diseases such as mesothelioma and pancreatic cancer
• H-CYTE plans to submit the Pre-IND submission for Jantibody in the second half of 2022
• Plan to file for Orphan Drug Designation for Jantibody along with IND submission, which would grant the benefit of 7-year market exclusivity

“Jantibody is a significant addition to our immunotherapeutics portfolio of products under development,” said Michael Yurkowsky, H-CYTE’s Chief Executive Officer. “The H-CYTE team is excited to further the prospect of life extending care for those diagnosed with ovarian cancer, the fifth leading cause of cancer-related death in women. The acquisition of Jantibody demonstrates H-CYTE’s transformation into a hybrid-biopharmaceutical company.”

Jantibody is a novel cancer immunotherapeutic agent that has demonstrated robust efficacy in controlling ovarian cancer and mesothelioma in preclinical models of these diseases. The Jantibody molecule was developed and refined at the Vaccine and Immunotherapy Center at MGH and Harvard Medical School by Dr. Jeffrey Gelfand and Dr. Mark Poznansky. This molecule is a fusion protein between a broadly immune activating protein called MTBhsp70 and an immune targeting molecule called a single chain antibody which causes the molecule to specifically attach to tumor cells and stimulate a robust immune response specifically around these malignant cells resulting in their death.

Jantibody has been shown to work even more effectively in combination with immune checkpoint inhibitors and a CXCR4 antagonist in preclinical models of cancer. The plan at Jantibody Inc. is to take this new immunotherapeutic molecule into first in human testing for ovarian cancer, which remains a very difficult to treat disease with current standard of care approaches. As of today, ovarian cancer occurs in one in 78 women in the United States.

About H-CYTE, Inc.

H-CYTE is a medical biosciences company. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While H-CYTE believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in H-CYTE’s filings with the SEC, including but not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. H-CYTE expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

H-CYTE Investor Contact:

Alpha IR Group
HCYT@alpha-ir.com
312-445-2870

Source: H-CYTE, Inc.

FAQ

What is H-CYTE's acquisition of Jantibody about?

H-CYTE is acquiring Jantibody, an immunotherapeutic agent for ovarian cancer, to expand its asset portfolio.

How will Jantibody impact H-CYTE's business?

Jantibody's acquisition aims to enhance H-CYTE's offerings in cancer treatment and potentially lead to significant market opportunities.

What is the strategic importance of Jantibody for H-CYTE?

Jantibody represents a step towards H-CYTE's transformation into a hybrid-biopharmaceutical company targeting serious diseases.

When does H-CYTE plan to file for Orphan Drug Designation for Jantibody?

H-CYTE plans to file for Orphan Drug Designation alongside its IND submission in the second half of 2022.

What diseases could Jantibody potentially treat?

While focused on ovarian cancer, Jantibody may also have applications in treating mesothelioma and pancreatic cancer.